...
首页> 外文期刊>Cytotechnology >Replating of bioreactor expanded human bone marrow results in extended growth of primitive and mature cells
【24h】

Replating of bioreactor expanded human bone marrow results in extended growth of primitive and mature cells

机译:更换生物反应器扩增的人骨髓可导致原始细胞和成熟细胞的扩展生长

获取原文

摘要

The capability to expand human bone marrow mononuclear cells (BM MNC) in high density perfusion culture chambers (bioreactors) has recently been developed. In these bioreactors, total cell colony-forming unit-granulocyte/macrophage (CFU-GM), and long-term culture-initiating cell (LTC-IC) numbers increase significantly over a 14-day period. However, cell growth ceases after the 14-day period, possibly due to cell density limitations. Because of the remaining presence of early cells, it should be feasible to replate the cells and obtain continued expansion. In this study, we demonstrate that bioreactors generate cells, which upon replating into secondary bioreactors, lead to continued cell, CFU-GM, and LTC-IC8 (measured after 8 weeks of secondary culture) expansion. A two-stage protocol, involving the replating of cells on days 9 to 12 of culture into new bioreators at the original seeding density, yielded greater than 50-fold cell expansion from BM MNC in 25 days. CFU-GM were expanded inhibitory factor (LIF) had no significant effect on total cells, CFU-GM, or LTC-IC5 in this system. We conclude that two-stage bioreactor cultures are capable of supporting extended growth of human BM MNC, CFU-GM, and LTC-IC8. The continued expansion of these primitive cells in the second stage of culture suggests that primitive cells with significant proliferative potential were generated in this system, and previous data on LTC-IC5 expansion has now been extended to LTC-IC8 expansion. Further optimization of culture conditions is likely to improve on the results obtained here, thus making perfusion bioreactor culture correspondingly more attractive for expanding BM MNC for BM transplantation.
机译:最近已经开发出在高密度灌注培养室(生物反应器)中扩增人骨髓单核细胞(BM MNC)的能力。在这些生物反应器中,总细胞集落形成单位-粒细胞/巨噬细胞(CFU-GM)和长期培养起始细胞(LTC-IC)数量在14天的时间内显着增加。但是,在14天后,细胞生长会停止,这可能是由于细胞密度的限制。由于早期细胞仍然存在,因此重新接种细胞并获得持续的扩增应该是可行的。在这项研究中,我们证明了生物反应器会产生细胞,然后将其重铺入二级生物反应器中,从而导致细胞,CFU-GM和LTC-IC8的持续扩增(在二级培养8周后测量)。一个分两阶段的方案,涉及在培养的第9天至第12天将细胞以原始接种密度重新接种到新的生物反应器中,在25天之内从BM MNC产生大于50倍的细胞扩增。 CFU-GM是扩展抑制因子(LIF),在该系统中对总细胞,CFU-GM或LTC-IC5没有明显影响。我们得出结论,两阶段生物反应器培养能够支持人类BM MNC,CFU-GM和LTC-IC8的扩展生长。这些原始细胞在培养的第二阶段的持续扩增表明,在该系统中产生了具有显着增殖潜能的原始细胞,有关LTC-IC5扩增的先前数据现已扩展至LTC-IC8扩增。培养条件的进一步优化可能会改善此处获得的结果,从而使灌注生物反应器培养物相应地对于扩大BM MNC用于BM移植更具吸引力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号